Rtw Investments Adds $10M in Centessa Pharmaceuticals plc ($CNTA)

Rtw Investments has increased its stake in Centessa Pharmaceuticals plc (NasdaqGS: CNTA) by 14.7%, according to a recent SEC filing. The investment firm added 263,338 shares, boosting its total holdings to 2,054,175 shares as of the reporting period. The value of this position is approximately $81.59 million.

What Changed in Rtw Investments' Centessa Pharmaceuticals Position

Rtw Investments' decision to add 263,338 shares to its Centessa Pharmaceuticals holdings represents a 14.7% increase, bringing its total to 2,054,175 shares. This move underscores the firm's continued interest in the biotechnology company, with the reported value of its stake at around $81.59 million.

Other Institutional Activity in Centessa Pharmaceuticals

In other institutional activity, Medicxi Ventures Management maintained its position in Centessa Pharmaceuticals with 19,963,157 shares valued at about $792.94 million. Avoro Capital Advisors reduced its holdings by 3,125,100 shares, leaving it with 11,430,455 shares worth approximately $454.02 million. Adage Capital Partners also trimmed its position by 2,356,731 shares, holding 8,925,010 shares valued at $354.50 million. Meanwhile, Pentwater Capital Management acquired 8,170,000 shares, reaching a total position valued at $324.51 million.

Centessa Pharmaceuticals Stock Snapshot

Shares of Centessa Pharmaceuticals traded near $39.72. The company has a market cap of approximately $6.15 billion and a beta of 1.121, indicating moderate volatility compared to the market. The stock has traded between $12.05 and $40.26 over the past year, with a 50-day moving average of $39.64 and a 200-day moving average of $28.50. Centessa's financial health appears strong with a current ratio of 9.534 and a quick ratio of 9.27, though it carries a debt-to-equity ratio of 24.327.

Recent Earnings

Centessa Pharmaceuticals reported a net margin of 0.0% and a return on equity of -57.38%, with an EPS of -$1.78. The company did not post a positive P/E ratio due to its lack of profitability. The next earnings report is scheduled for May 14, 2026.

Insider Buying and Selling at Centessa Pharmaceuticals plc

Insider activity at Centessa Pharmaceuticals included CEO Mario Alberto Accardi selling 604 shares on May 1, 2026, at an average price of $39.42. Chief People Officer Karen Anderson was involved in multiple transactions on March 26, 2026, selling 41,076 shares at $30.12 under a planned sale, while also buying the same amount at $8.01. Chief Business Officer Gregory Weinhoff also executed trades on March 26, 2026, selling 23,998 shares.

Analysts Set New Price Targets

On April 20, 2026, Wells Fargo downgraded Centessa Pharmaceuticals to a hold rating with a $42.00 price target. Similarly, Leerink Partners downgraded the stock to hold with a $40.00 target on April 1, 2026. Wolfe Research initiated coverage with a buy rating and a $40.00 target on February 24, 2026. The consensus among analysts is a buy rating, with a mean target price of $44.17 based on six opinions.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a biotechnology firm based in Altrincham, United Kingdom. It focuses on discovering and developing neuroscience therapeutics, particularly orexin-based treatments. The company is working on ORX750, ORX142, and ORX489 for various neurological conditions, and has an immuno-oncology platform called LockBody. Founded in 2020, Centessa operates in both the UK and the US under the leadership of CEO Dr. Mario Alberto Accardi.

Bottom Line

Rtw Investments' increase in Centessa Pharmaceuticals shares highlights its interest in the company's potential in biotechnology. This activity is part of a broader landscape of institutional moves around Centessa, with some firms trimming positions while others increase their stakes. Investors keep an eye on such filings to gauge institutional sentiment, though it's crucial to remember these are backward-looking indicators reflecting past positions.